Dr. Li Xie 谢李
Chief Physician
Department of Head and Neck Surgery, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of thyroid, parathyroid, oral and maxillofacial, salivary gland, laryngeal, hypopharyngeal, nasal, sinus, and skull base tumors. Expertise includes function-preserving surgery, active surveillance for thyroid cancer, and multidisciplinary care for locally advanced head and neck cancers.
Dr. Li Xie holds a medical doctorate from Central South University Xiangya Hospital (2010). A Chief Physician at Hunan Cancer Hospital since 2023, Dr. Xie completed advanced fellowships in Germany (2015), the UK (2018), and Japan (2024). Research focuses on facial lymph node metastasis in oral squamous cell carcinoma and modified maxillary external rotation approaches.
Professional roles
- Member, Thyroid Cancer Professional Committee, China Anti-Cancer Association (Youth Committee)
- Member, Repair and Reconstruction Branch, Chinese Association of Rehabilitation Medicine (Youth Committee)
- Member, Parathyroid Group, Thyroid Disease Professional Committee, China International Exchange and Promotion Association for Medical and Healthcare
- Vice Chair, Oncology Professional Committee (Youth Committee), Hunan Medical Association
Name order: in Chinese the family name comes first (Xie Li). Papers usually list the name as Li Xie or Xie L.
Selected publications
13 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Discov, 2023 (first author): Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis. PubMed 37779163
- Sci Rep, 2023 (senior author): Author Correction: Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance. PubMed 36720899
- Sci Rep, 2022 (senior author): Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance. PubMed 36450751
- Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2022 (senior author): [Application of lateral upper arm free flap in the repair of postoperative defects of oral cancer]. PubMed 36319128
- Dis Markers, 2022 (senior author): FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. PubMed 35401877
- Front Oncol, 2020 (first author): Modified Maxillary-Swing Approach for Resection of Primary Malignancies in the Pterygopalatine Fossa. PubMed 33240804
- J Oral Maxillofac Surg, 2018 (first author): In-Continuity Neck Dissection: Long-Term Oncological Outcomes in Squamous Cell Carcinoma of the Buccal Mucosa. PubMed 29195080
- Tumour Biol, 2016 (first author): Facial lymph node involvement as a prognostic factor for patient survival in oral cavity squamous cell carcinoma. PubMed 26449832
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion